Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.

@article{Saiz2015TherapeuticCO,
  title={Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.},
  author={Albert Saiz and Sheila Mora and Jos{\'e} L Blanco},
  journal={Neurologia},
  year={2015},
  volume={30 4},
  pages={214-22}
}
INTRODUCTION Non-adherence to disease-modifying therapies (DMTs) in multiple sclerosis may be associated with reduced efficacy. We assessed compliance, the reasons for non-compliance, treatment satisfaction, and quality of life (QoL) of patients treated with first-line therapies. METHODS A cross-sectional, multicenter study was conducted that included relapsing multiple sclerosis patients. Compliance in the past month was assessed using Morisky-Green test. Seasonal compliance and reasons for… CONTINUE READING